The Geneva University Hospitals is one of the five university hospitals of Switzerland, and the largest one in the country. It is one of the largest hospitals in Europe. First founded in 1535, the creation of the HUG dates back to 1995 as a merger of all public hospitals in Geneva.

During the past decade, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Danish Head and Neck Cancer Group" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie" are "Colorectal Cancer" (2 trials), "Liver Metastases" (2 trials), "Advanced Colorectal Cancer" (1 trials), "Breast Cancer" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie" in a lesser frequency.

Most popular intervention types in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie" are "Drug" (5 trials), "Radiation" (3 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Radiotherapy" (2 trials), "Bevacizumab" (1 trials), "Cisplatin" (1 trials), "Degarelix" (1 trials) and "Durvalumab (MEDI4736)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie" are 5 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".